Selected research
Industry Growth & Trends
Global Insulin Biologics and Biosimilars Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Insulin Biologics and Biosimilars market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Insulin Biologics and Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Insulin Biologics and Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Insulin Biologics and Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Insulin Biologics and Biosimilars market include Tonghua Dongbao, Sanofi, Novo Nordisk, Eli Lilly, Wockhardt, United Laboratory, Geropharm, Gan&Lee and Biocon, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Insulin Biologics and Biosimilars market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Insulin Biologics and Biosimilars market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Insulin Biologics and Biosimilars market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Insulin Biologics and Biosimilars.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Insulin Biologics and Biosimilars market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Insulin Biologics and Biosimilars Market by Company
Tonghua Dongbao
Sanofi
Novo Nordisk
Eli Lilly
Wockhardt
United Laboratory
Geropharm
Gan&Lee
Biocon
Insulin Biologics and Biosimilars Segment by Type
Insulin Biologics
Insulin Biosimilars
Insulin Biologics and Biosimilars Segment by Application
Hospital
Retail Pharmacy
Other
Insulin Biologics and Biosimilars Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Insulin Biologics and Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Insulin Biologics and Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Insulin Biologics and Biosimilars.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Insulin Biologics and Biosimilars companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Insulin Biologics
- Insulin Biosimilars
Applications
- Hospital
- Retail Pharmacy
- Other
Companies covered
- Tonghua Dongbao
- Sanofi
- Novo Nordisk
- Eli Lilly
- Wockhardt
- United Laboratory
- Geropharm
- Gan&Lee
- Biocon
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Insulin Biologics and Biosimilars Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Insulin Biologics and Biosimilars Market Size by Region (2021-2032)
- 1.4.1 Global Insulin Biologics and Biosimilars Market Size by Region (2021-2026)
- 1.4.2 Global Insulin Biologics and Biosimilars Market Size by Region (2027-2032)
- 1.5 Key Regions Insulin Biologics and Biosimilars Market Size (2021-2032)
- 1.5.1 North America Insulin Biologics and Biosimilars Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Insulin Biologics and Biosimilars Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Insulin Biologics and Biosimilars Market Size Growth Rate (2021-2032)
- 1.5.4 South America Insulin Biologics and Biosimilars Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Insulin Biologics and Biosimilars Market Size Growth Rate (2021-2032)
2 Insulin Biologics and Biosimilars Market by Type
- 2.1 Type Introduction
- 2.1.1 Insulin Biologics
- 2.1.2 Insulin Biosimilars
- 2.2 Global Insulin Biologics and Biosimilars Market Size by Type
- 2.2.1 Global Insulin Biologics and Biosimilars Market Size Overview by Type (2021-2032)
- 2.2.2 Global Insulin Biologics and Biosimilars Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Insulin Biologics and Biosimilars Market Size Forecasted by Type (2027-2032)
- 2.3 Global Insulin Biologics and Biosimilars Market Size by Regions
- 2.3.1 North America Insulin Biologics and Biosimilars Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Insulin Biologics and Biosimilars Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Insulin Biologics and Biosimilars Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Insulin Biologics and Biosimilars Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Insulin Biologics and Biosimilars Market Size Breakdown by Type (2021-2026)
3 Insulin Biologics and Biosimilars Market by Application
- 3.1 Type Introduction
- 3.1.1 Hospital
- 3.1.2 Retail Pharmacy
- 3.1.3 Other
- 3.2 Global Insulin Biologics and Biosimilars Market Size by Application
- 3.2.1 Global Insulin Biologics and Biosimilars Market Size Overview by Application (2021-2032)
- 3.2.2 Global Insulin Biologics and Biosimilars Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Insulin Biologics and Biosimilars Market Size Forecasted by Application (2027-2032)
- 3.3 Global Insulin Biologics and Biosimilars Market Size by Regions
- 3.3.1 North America Insulin Biologics and Biosimilars Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Insulin Biologics and Biosimilars Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Insulin Biologics and Biosimilars Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Insulin Biologics and Biosimilars Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Insulin Biologics and Biosimilars Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Insulin Biologics and Biosimilars Industry Trends
- 4.2 Insulin Biologics and Biosimilars Industry Drivers
- 4.3 Insulin Biologics and Biosimilars Industry Opportunities and Challenges
- 4.4 Insulin Biologics and Biosimilars Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Insulin Biologics and Biosimilars Revenue (2021-2026)
- 5.2 Global Insulin Biologics and Biosimilars Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Insulin Biologics and Biosimilars Key Company Headquarters & Area Served
- 5.4 Global Insulin Biologics and Biosimilars Company, Product Type & Application
- 5.5 Global Insulin Biologics and Biosimilars Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Insulin Biologics and Biosimilars Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Insulin Biologics and Biosimilars Players Market Share by Revenue in 2025
- 5.6.3 2025 Insulin Biologics and Biosimilars Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Tonghua Dongbao
- 6.1.1 Tonghua Dongbao Company Information
- 6.1.2 Tonghua Dongbao Business Overview
- 6.1.3 Tonghua Dongbao Insulin Biologics and Biosimilars Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Tonghua Dongbao Insulin Biologics and Biosimilars Product Portfolio
- 6.1.5 Tonghua Dongbao Recent Developments
- 6.2 Sanofi
- 6.2.1 Sanofi Company Information
- 6.2.2 Sanofi Business Overview
- 6.2.3 Sanofi Insulin Biologics and Biosimilars Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Sanofi Insulin Biologics and Biosimilars Product Portfolio
- 6.2.5 Sanofi Recent Developments
- 6.3 Novo Nordisk
- 6.3.1 Novo Nordisk Company Information
- 6.3.2 Novo Nordisk Business Overview
- 6.3.3 Novo Nordisk Insulin Biologics and Biosimilars Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Novo Nordisk Insulin Biologics and Biosimilars Product Portfolio
- 6.3.5 Novo Nordisk Recent Developments
- 6.4 Eli Lilly
- 6.4.1 Eli Lilly Company Information
- 6.4.2 Eli Lilly Business Overview
- 6.4.3 Eli Lilly Insulin Biologics and Biosimilars Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Eli Lilly Insulin Biologics and Biosimilars Product Portfolio
- 6.4.5 Eli Lilly Recent Developments
- 6.5 Wockhardt
- 6.5.1 Wockhardt Company Information
- 6.5.2 Wockhardt Business Overview
- 6.5.3 Wockhardt Insulin Biologics and Biosimilars Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Wockhardt Insulin Biologics and Biosimilars Product Portfolio
- 6.5.5 Wockhardt Recent Developments
- 6.6 United Laboratory
- 6.6.1 United Laboratory Company Information
- 6.6.2 United Laboratory Business Overview
- 6.6.3 United Laboratory Insulin Biologics and Biosimilars Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 United Laboratory Insulin Biologics and Biosimilars Product Portfolio
- 6.6.5 United Laboratory Recent Developments
- 6.7 Geropharm
- 6.7.1 Geropharm Company Information
- 6.7.2 Geropharm Business Overview
- 6.7.3 Geropharm Insulin Biologics and Biosimilars Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Geropharm Insulin Biologics and Biosimilars Product Portfolio
- 6.7.5 Geropharm Recent Developments
- 6.8 Gan&Lee
- 6.8.1 Gan&Lee Company Information
- 6.8.2 Gan&Lee Business Overview
- 6.8.3 Gan&Lee Insulin Biologics and Biosimilars Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Gan&Lee Insulin Biologics and Biosimilars Product Portfolio
- 6.8.5 Gan&Lee Recent Developments
- 6.9 Biocon
- 6.9.1 Biocon Company Information
- 6.9.2 Biocon Business Overview
- 6.9.3 Biocon Insulin Biologics and Biosimilars Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Biocon Insulin Biologics and Biosimilars Product Portfolio
- 6.9.5 Biocon Recent Developments
7 North America
- 7.1 North America Insulin Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Insulin Biologics and Biosimilars Market Size by Country (2021-2026)
- 7.3 North America Insulin Biologics and Biosimilars Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Insulin Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Insulin Biologics and Biosimilars Market Size by Country (2021-2026)
- 8.3 Europe Insulin Biologics and Biosimilars Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Insulin Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Insulin Biologics and Biosimilars Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Insulin Biologics and Biosimilars Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Insulin Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Insulin Biologics and Biosimilars Market Size by Country (2021-2026)
- 10.3 South America Insulin Biologics and Biosimilars Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Insulin Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Insulin Biologics and Biosimilars Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Insulin Biologics and Biosimilars Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst